Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för fosamprenavir. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

8 träffar

Bibliografisk träff 2014-08-25

Effect of fosamprenavir-ritonavir on the pharmacokinetics of dolutegravir in healthy subjects.

Song I, Borland J, Chen S, Peppercorn A, Wajima T, Piscitelli SC.

Antimicrob Agents Chemother · clinical trial; research support, non-u.s. gov't; research-article; journal article · DOI 10.1128/aac.03282-14

Bibliografisk träff 2014-08-01

Antiviral drug allergy.

Milpied-Homsi B, Moran EM, Phillips EJ.

Immunol Allergy Clin North Am · research-article; review; journal article · DOI 10.1016/j.iac.2014.04.011

Bibliografisk träff 2014-05-23

Effect of fosamprenavir/ritonavir on the pharmacokinetics of single-dose olanzapine in healthy volunteers.

Jacobs BS, Colbers AP, Velthoven-Graafland K, Schouwenberg BJ, Burger DM.

Int J Antimicrob Agents · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1016/j.ijantimicag.2014.03.014

Bibliografisk träff 2014-03-01

Post-licensing safety of fosamprenavir in HIV-infected children in Europe.

Judd A, Duong T, Galli L, Goetghebuer T, Ene L, Noguera Julian A, Ramos Amador JT, Pimenta JM, Thorne C, Giaquinto C, European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group in EuroCoord.

Pharmacoepidemiol Drug Saf · research-article; journal article · DOI 10.1002/pds.3543

Bibliografisk träff 2014-01-01

Pharmacokinetics and 48-week safety and antiviral activity of fosamprenavir-containing regimens in HIV-infected 2- to 18-year-old children.

Fortuny C, Duiculescu D, Cheng K, Garges HP, Cotton M, Tamarirt DP, Ford SL, Wire MB, Givens N, Ross LL, Lou Y, Perger T, Sievers J.

Pediatr Infect Dis J · clinical trial, phase ii; research support, non-u.s. gov't; research-article; multicenter study; journal article · DOI 10.1097/inf.0b013e3182a1126a

Bibliografisk träff 2013-04-01

Steady-state pharmacokinetics, cord blood concentrations, and safety of ritonavir-boosted fosamprenavir in pregnancy.

Cespedes MS, Castor D, Ford SL, Lee D, Lou Y, Pakes GE, Aberg JA.

J Acquir Immune Defic Syndr · clinical trial; research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1097/qai.0b013e318285d918

Bibliografisk träff 2011-11-18

Interactions between buprenorphine and the protease inhibitors darunavir-ritonavir and fosamprenavir-ritonavir.

Gruber VA, Rainey PM, Moody DE, Morse GD, Ma Q, Prathikanti S, Pade PA, Alvanzo AA, McCance-Katz EF.

Clin Infect Dis · historical article; controlled clinical trial; research-article; journal article; research support, n.i.h., extramural · DOI 10.1093/cid/cir799

Bibliografisk träff 2006-08-01

The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial.

Eron J, Yeni P, Gathe J, Estrada V, DeJesus E, Staszewski S, Lackey P, Katlama C, Young B, Yau L, Sutherland-Phillips D, Wannamaker P, Vavro C, Patel L, Yeo J, Shaefer M, KLEAN study team.

Lancet · research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1016/s0140-6736(06)69155-1